Titan Medical to Present and Exhibit at the Society of Robotic Surgery 2018 Annual Meeting

TORONTO, June 13, 2018 -- Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (OTCQB:TITXF), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that David McNally, President and CEO of Titan Medical, will present in the plenary session on Monday, June 18 at the Society of Robotic Surgery 2018 Annual Meeting in Stockholm. This industry-focused plenary session will feature executives from companies recognized for current and promising technology platforms in robotic surgery.

Two abstracts highlighting multi-disciplinary preclinical work from two of Titan’s Centers of Excellence, Florida Hospital Nicholson Center and IHU Strasbourg, will be presented at the meeting in the form of Poster Presentations. These abstracts will also be included in the Journal of Robotic Surgery , a peer-reviewed medical journal covering robotic surgery and an official journal of SRS. The SPORT Surgical System will also be highlighted in several presentations in General Surgery, Gynecology and Colorectal tracks throughout the meeting. Titan Medical will showcase its technology and multi-specialty preclinical feasibility videos at its booth in the Exhibit Hall.

David McNally, President and CEO of Titan Medical, said, “We are delighted with our comprehensive participation in the Society of Robotic Surgery 2018 Annual Meeting, where we will be among clinical and industry experts in the field of robotic surgery. The acceptance of two abstracts highlighting our preclinical feasibility work and several presentations referencing the SPORT Surgical System as a promising single-port robotic technology platform further demonstrates enthusiasm for single-port robotic surgery in a variety of surgical disciplines. We look forward to sharing our vision and commitment to advancing robotic surgery during the industry plenary session on the first day of the meeting.”

The Society of Robotic Surgery 2018 Annual Meeting is designed to be the most comprehensive robotic surgery symposium, featuring internationally renowned faculty who are dedicated experts in their fields of study.

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure current or prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Contacts:

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
     or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Titan Medical Announces Voting Results From Its Annual AND SPECIAL Meeting of Shareholders

TORONTO, June 15, 2018 -- Titan Medical Inc. (“ Titan ” or the “ Company ”) (TSX:TMD) (OTCQB:TITXF), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery, reported shareholder vote results from the Company’s Annual and Special Meeting held on Thursday, June 14, 2018.

All of management’s nominees for election were duly elected as directors of the Company by the shareholders present or represented by proxy at the meeting. The results of the vote were reported to the meeting by Computershare, which acted as scrutineer at the meeting, as follows:

A total of 297,193,033 (or 70.78%) of the 419,888,311 common shares outstanding were voted at the meeting.

Shareholders passed the motion (with 46,883,459 votes (71.36%) for and 18,812,932 votes (28.64%) against) approving the stock option plan of the Company.

Shareholders passed the motion (with 261,778,215 votes (88.08%) for and 35,414,816 votes (11.92%) against) authorizing the consolidation of the outstanding common shares of the Company on the basis of a ratio to be determined by the board of directors of the Company in its sole discretion, within a range of one post-consolidation common share for every 5 to 30 outstanding pre-consolidation common shares of the Company.

The appointment of BDO Canada LLP as Auditors of the Company was approved by shareholders (with 287,610,199 votes (96.78%) for and 9,582,834 votes (3.22%) withheld) in respect of the motion.

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com .

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

ContactS:

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
     or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Titan Medical Announces Completion of 1-for-30 Reverse Stock Split

TORONTO, June 19, 2018 -- Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (OTCQB:TITXF), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery, announces that it has completed the previously announced consolidation (the “Consolidation”) of its outstanding common shares (the “Common Shares”) on the basis of the ratio of 1 post-Consolidation Common Share for 30 pre-Consolidation Common Shares. The Consolidation took effect prior to the opening of trading on Tuesday, June 19, 2018 and is being undertaken in connection with Titan’s application to list its Common Shares on the Nasdaq Stock Market LLC (“Nasdaq”).

Effect on Outstanding Common Shares

The Company’s Common Shares continue to trade under its existing symbol, TMD, on the Toronto Stock Exchange (the “TSX”). Immediately prior to Consolidation, there were 419,888,311 Common Shares issued and outstanding and immediately following the Consolidation, there are 13,996,277 Common Shares issued and outstanding, subject to rounding for any fractional shares. No fractional shares were issued as a result of the Consolidation. Fractional interests of 0.5 or greater will be rounded up to the nearest whole number of shares and fractional interests of less than 0.5 will be rounded down to the nearest whole number of shares.

Shareholder Authorization

The Consolidation was approved by special resolution of the shareholders of the Company (the “Special Resolution”) at the annual and special meeting of shareholders on June 14, 2018 (the “Meeting”). The Special Resolution was approved by 88.08% of votes at the Meeting.

Registered Holders.

Registered shareholders holding certificates representing Common Shares have been mailed a letter of transmittal advising of the share consolidation and instructing them to surrender their share certificates representing pre-Consolidation Common Shares to Computershare Investor Services Inc. for replacement certificates or direct registration advice representing their post -Consolidation Common Shares. Until surrendered for exchange, following the date hereof, each share certificate formerly representing pre-Consolidation Common Shares will be deemed to represent, in lieu of the number of pre-Consolidation shares imprinted on the certificate, the number of whole post-Consolidation Common Shares to which the holder is entitled as a result of the 1:30 Consolidation.

Holders of Common Shares of the Company who hold uncertificated Common Shares (that is Common Shares held in book-entry form and not represented by a physical share certificate), either as registered holders or beneficial owners, will have their existing book-entry account(s) electronically adjusted by the Company’s transfer agent or, for beneficial shareholders, by their brokerage firms, banks, trusts or other nominees that hold in street name for their benefit. Such holders do not need to take any additional actions to exchange their pre-Consolidation Common Shares for post-Consolidation Common Shares.

Non-Registered Holders. Beneficial shareholders holding their Common Shares through a bank, broker or other nominee should note that such banks, brokers or other nominees may have different procedures for processing the consolidation than those that have been put in place by the Company for registered shareholders. If you hold your Common Shares with such a bank, broker or other nominee, and if you have questions in this regard, you are encouraged to contact your nominee.

The Company currently anticipates that, subject to the receipt of all required approvals, its Common Shares will begin trading on the Nasdaq before the end of June 2018. The listing of the Company’s Common Shares on the Nasdaq remains subject to the approval of that exchange and the satisfaction of all applicable listing requirements.

Convertible Securities. The exercise or conversion price and/or the number of Common Shares issuable under outstanding convertible securities, including warrants and stock options, exercisable for, or convertible or exchangeable into, pre– Consolidation Common Shares (“Convertible Securities”) that have not been exercised or cancelled prior to the date hereof will be proportionately adjusted pursuant to the terms thereof based on the same exchange ratio described above and each holder of pre–Consolidation Convertible Securities will become entitled to receive post–Consolidation Common Shares pursuant to such adjusted terms, where required and subject to TSX approval. The trading symbol for listed warrants will not change due to the proposed share consolidation.

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Contacts:

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
    or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Titan Medical’s Head of Intellectual Property Recognized as a Global IP Strategy Leader by Intellectual Asset Management

TORONTO, June 20, 2018 -- Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (OTCQB:TITXD), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery, announces that Jasminder Brar, Titan Medical’s Director of Strategic Development and Intellectual Property, was recognized by Intellectual Asset Management (IAM) as a global IP strategy leader.

IAM, a leading IP business media platform, named Mr. Brar to the 2018 edition of IAM Strategy 300 – The World’s Leading IP Strategists . The guide lists the individuals that in-depth research undertaken by a team in London, Washington, DC and Hong Kong has shown possess world-class skills in the development and roll-out of strategies that maximize the value of patents, copyright, trademarks and other IP rights. Included in the guide are third-party IP advisers as well as individuals working inside operating companies, reflecting the growing importance that businesses across the world attach to having in-house IP value creation expertise.

This is the fourth consecutive year that Mr. Brar has been included in the guide.

“Intellectual property continues to be absolutely vital to our success and we are proud that Jasminder’s leadership of our efforts and accomplishments has been recognized,” said David McNally, President and CEO of Titan Medical. “I want to congratulate Jasminder on his inclusion in the IAM Strategy 300 for the fourth consecutive year and acknowledge his leadership and knowhow in advancing our strategic intellectual property efforts.”

The 2018 edition of the guide can be found here and a press release by IAM can be found here .

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com .

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Contacts:

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
   or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Titan Medical Common Stock to Trade on Nasdaq

TORONTO, June 27, 2018 -- Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that shares of its common stock were approved for listing on the Nasdaq Capital Market. Titan Medical’s common stock will commence trading on the Nasdaq Capital Market on June 27, 2018 under the symbol TMDI.

Titan Medical’s common stock will continue to trade uninterrupted on the Toronto Stock Exchange (TSX) under the symbol TMD. Previously Titan Medical’s common stock traded on the OTC market under the symbols TITXF and TITXD.

“We are pleased to achieve this significant milestone and look forward to shares of our common stock trading on Nasdaq,” said David McNally, CEO of Titan Medical. “As a dual-listed company on both Nasdaq and the Toronto Stock Exchange, we have the opportunity to broaden our exposure to U.S. institutional investors, diversify our shareholder base, expand our access to capital and increase liquidity.”

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com .

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Contacts:

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
   or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Titan Medical Appoints Medtech Industry Veteran Domenic Serafino to Its
Board of Directors

TORONTO, June 28, 2018 -- Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces the appointment of Domenic Serafino to its board of directors, effective June 28. Mr. Serafino has held executive positions with various Canadian medical technology companies for more than 20 years. His appointment increases the size of Titan’s board to six directors.

“We are delighted to welcome Dom to our board of directors,” said John E. Barker, Director and Chairman of Titan Medical. “His significant experience leading sales, marketing and operations, along with in-depth knowledge of the regulatory paths at several very successful companies will be of benefit to Titan as we complete development of our SPORT single-port robotic surgery system and prepare regulatory submissions during the next two years. In addition, we welcome Domenic’s experience with Nasdaq-listed companies.”

Mr. Serafino is Chairman and Chief Executive Officer of Venus Concept Ltd., an aesthetic medical device company he founded in 2010. Mr. Serafino built the company to approximately $120 million in annual revenue with sales in more than 60 countries, and 450 employees in 27 markets. Previously he was with aesthetic medical laser company Syneron, now Candela Syneron, as president for North America, and was instrumental in taking the company public on Nasdaq in August 2004. During his five-year tenure, the company’s revenue increased from $0 to approximately $65 million, with a market value of approximately $1.3 billion. Prior to Syneron Mr. Serafino was a partner, president and chief operating officer of Canada’s largest laser distribution company, Sigmacon Group, from 1995 to 2001.

Commenting on his appointment to Titan’s board, Mr. Serafino said, “I am pleased to be joining Titan Medical’s board at such a pivotal moment in the company’s development as it prepares to enter the rapidly-growing robotic surgery market. With its stock now listed on Nasdaq and my experience with public medical technology companies, I believe I can have a positive impact on the company’s development and progress.”

Mr. Serafino serves as Chairman of the Board of Directors of Venus Concepts and also sits on the Board of Directors of Scientus Pharma, a privately-held biopharmaceutical company based in Toronto. He holds a general business administration degree from Centennial College of Applied Arts and Technology in Toronto.

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com .

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Contacts:

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
     or
Bruce Voss
(310) 691-7100
bvoss@lhai.com